ATE484279T1 - Isosorbid-mononitrat-derivate zur behandlung von darmerkrankungen - Google Patents

Isosorbid-mononitrat-derivate zur behandlung von darmerkrankungen

Info

Publication number
ATE484279T1
ATE484279T1 AT07858187T AT07858187T ATE484279T1 AT E484279 T1 ATE484279 T1 AT E484279T1 AT 07858187 T AT07858187 T AT 07858187T AT 07858187 T AT07858187 T AT 07858187T AT E484279 T1 ATE484279 T1 AT E484279T1
Authority
AT
Austria
Prior art keywords
treatment
isosorbide mononitrate
intestinal diseases
mononitrate derivatives
derivatives
Prior art date
Application number
AT07858187T
Other languages
German (de)
English (en)
Inventor
Moliner Jose Repolles
Coy Francisco Pubill
Mancini Marisabel Mourelle
Original Assignee
Lacer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38043051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE484279(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lacer Sa filed Critical Lacer Sa
Application granted granted Critical
Publication of ATE484279T1 publication Critical patent/ATE484279T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT07858187T 2006-12-28 2007-12-27 Isosorbid-mononitrat-derivate zur behandlung von darmerkrankungen ATE484279T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06380338A EP1941876A1 (en) 2006-12-28 2006-12-28 Isosorbide mononitrate derivatives for the treatment of Inflammation and ocular hypertension
PCT/EP2007/064591 WO2008080955A1 (en) 2006-12-28 2007-12-27 Isosorbide mononitrate derivatives for the treatment of intestinal disorders

Publications (1)

Publication Number Publication Date
ATE484279T1 true ATE484279T1 (de) 2010-10-15

Family

ID=38043051

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07858187T ATE484279T1 (de) 2006-12-28 2007-12-27 Isosorbid-mononitrat-derivate zur behandlung von darmerkrankungen
AT07858167T ATE472324T1 (de) 2006-12-28 2007-12-27 Isosorbid-mononitrat-derivate zur behandlung von okularer hypertonie

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07858167T ATE472324T1 (de) 2006-12-28 2007-12-27 Isosorbid-mononitrat-derivate zur behandlung von okularer hypertonie

Country Status (21)

Country Link
US (1) US20080161389A1 (enExample)
EP (3) EP1941876A1 (enExample)
JP (2) JP2010514734A (enExample)
KR (2) KR20090112673A (enExample)
CN (2) CN101600425A (enExample)
AR (1) AR064543A1 (enExample)
AT (2) ATE484279T1 (enExample)
AU (2) AU2007341289B2 (enExample)
BR (2) BRPI0720663A2 (enExample)
CA (2) CA2674550A1 (enExample)
CL (2) CL2007003837A1 (enExample)
DE (2) DE602007009877D1 (enExample)
ES (3) ES2324130B1 (enExample)
IL (2) IL198912A0 (enExample)
MX (2) MX2009007038A (enExample)
NO (2) NO20092764L (enExample)
PL (2) PL2124930T3 (enExample)
RU (2) RU2009128970A (enExample)
UY (1) UY30847A1 (enExample)
WO (2) WO2008080939A1 (enExample)
ZA (2) ZA200903566B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2149576A1 (en) * 2008-07-22 2010-02-03 Lacer, S.A. Isosorbide Nitrates having vasodilating activity
EP2149577B1 (en) * 2008-07-22 2011-04-27 Lacer, S.A. New stereospecific method for the preparation of dioxa-bicyclooctane compounds
EP2177216A1 (en) * 2008-10-13 2010-04-21 Lacer, S.A. Use of dianhydrohexite mononitrate derivatives as healing agents
WO2010055138A1 (en) * 2008-11-14 2010-05-20 Lacer, S.A. New stereospecific method for the preparation of dioxa-bicyclooctane compounds
EP2199294A1 (en) * 2008-12-19 2010-06-23 Lacer, S.A. New stereospecific method for the preparation of dioxa bicyclooctane nitrate compounds
EP2515899B1 (en) * 2009-12-23 2016-05-25 ARCA biopharma, Inc. Methods and compositions for cardiovascular diseases and conditions
HK1217323A1 (zh) * 2013-03-05 2017-01-06 阿彻丹尼尔斯米德兰德公司 异己糖醇单三氟甲磺酸酯及其合成方法
WO2018224419A1 (en) 2017-06-06 2018-12-13 Nicox S.A. Nitric oxide donating isomannide derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2739689C2 (de) * 1977-09-02 1986-10-16 Euratom Thermische Wärmepumpe
JPS60149521A (ja) * 1984-01-18 1985-08-07 Eisai Co Ltd 高眼圧・緑内障治療・予防用点眼剤
US5573758A (en) * 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
US5925342A (en) * 1996-11-13 1999-07-20 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
GB9720797D0 (en) * 1997-09-30 1997-12-03 Rhodes John Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
ES2142773B1 (es) * 1998-10-07 2001-01-01 Lacer Sa Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia desminuida.
JP2004517940A (ja) * 2001-01-31 2004-06-17 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ピラゾロ［４，３−ｄ］ピリミジンおよびニトレートまたはチエノピリミジンおよびニトレートを含む医薬製剤
WO2003079997A2 (en) * 2002-03-21 2003-10-02 Cayman Chemical Company Prostaglandin f2 alpha analogs in combinaiotn with antimicrobials for treating glaucoma
CN1863905A (zh) * 2003-09-08 2006-11-15 得克萨斯系统大学董事会 通过用前列腺素或前列腺素类似物补充培养基加强体外胚发育的方法以及组合物
ES2258365B1 (es) * 2003-10-03 2007-12-01 Lacer, S.A. Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos.

Also Published As

Publication number Publication date
EP2124930B1 (en) 2010-10-13
JP2010514733A (ja) 2010-05-06
US20080161389A1 (en) 2008-07-03
AU2007341218B2 (en) 2010-09-09
BRPI0720664A2 (pt) 2014-01-14
EP2124930A1 (en) 2009-12-02
CA2674550A1 (en) 2008-07-10
AU2007341218A1 (en) 2008-07-10
IL198941A0 (en) 2010-02-17
ES2324130A1 (es) 2009-07-30
NO20092763L (no) 2009-07-27
AR064543A1 (es) 2009-04-08
CL2007003836A1 (es) 2008-07-11
AU2007341289B2 (en) 2010-08-26
ES2324130B1 (es) 2010-03-22
CL2007003837A1 (es) 2008-07-11
CN101600426A (zh) 2009-12-09
PL2114398T3 (pl) 2010-11-30
MX2009007038A (es) 2009-08-25
IL198912A0 (en) 2010-02-17
EP2114398A1 (en) 2009-11-11
WO2008080955A1 (en) 2008-07-10
KR20100100584A (ko) 2010-09-15
AU2007341289A1 (en) 2008-07-10
EP1941876A1 (en) 2008-07-09
PL2124930T3 (pl) 2011-04-29
NO20092764L (no) 2009-07-27
ZA200903566B (en) 2010-08-25
RU2009128968A (ru) 2011-02-10
KR20090112673A (ko) 2009-10-28
CA2674144A1 (en) 2008-07-10
EP2114398B1 (en) 2010-06-30
UY30847A1 (es) 2008-05-31
ATE472324T1 (de) 2010-07-15
CN101600425A (zh) 2009-12-09
RU2009128970A (ru) 2011-02-10
WO2008080939A1 (en) 2008-07-10
JP2010514734A (ja) 2010-05-06
BRPI0720663A2 (pt) 2014-01-14
ES2354317T3 (es) 2011-03-14
ES2348314T3 (es) 2010-12-02
DE602007009877D1 (de) 2010-11-25
CN101600426B (zh) 2012-07-25
DE602007007523D1 (de) 2010-08-12
ZA200903567B (en) 2010-08-25
MX2009007040A (es) 2009-08-25

Similar Documents

Publication Publication Date Title
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
ATE550329T1 (de) Heterobicyclische sulfonamidderivate zur behandlung von diabetes
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
EP2111223A4 (en) AMINO-DERIVED COMPOUNDS FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
EP2021352A4 (en) TREATMENT OF POOR FOLDING OF PROTEINS
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
EP2135858A4 (en) COMPOSITION FOR TREATING INFECTIOUS DISEASES
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
DE602005017503D1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE484279T1 (de) Isosorbid-mononitrat-derivate zur behandlung von darmerkrankungen
ATE537150T1 (de) Zur behandlung gynäkologischer erkrankungen geeignete pyrazolderivate
ATE438623T1 (de) Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
EP2210621A4 (en) COMPOSITION FOR TREATING JOINT DISEASE
EP1965827A4 (en) TREATMENT OF CONDITIONS RELATED TO DEMYELINATION
FI20095600L (fi) Koostumus ihosairauksien hoitoa varten
ATE525355T1 (de) 1-ä(4-äbenzoyl(methyl)aminoü-3- (phenyl)butylüazetidinderivate zur behandlung von gastrointestinalen erkrankungen 1
ATE482709T1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen
ATE439843T1 (de) S-mirtazapin zur behandlung von hitzewallungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties